Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

Summary

In a 48-week, phase 3, double-blind RCT (n=610), mazdutide 4 mg and 6 mg produced −11.0% and −14.0% mean weight loss at week 48 versus 0.3% with placebo and improved multiple cardiometabolic measures. Rates of ≥15% weight loss were 35.7% and 49.5% (vs 2.0% placebo); gastrointestinal events were the most common and were mostly mild–moderate.

Key Findings

• At week 32, mean weight change: −10.09% (4 mg), −12.55% (6 mg), vs +0.45% (placebo); ≥5% weight loss in 73.9% and 82.0% vs 10.5% (P<0.001).
• At week 48, mean weight change: −11.00% (4 mg), −14.01% (6 mg), vs 0.30% (placebo); ≥15% weight loss in 35.7% and 49.5% vs 2.0% (P<0.001).
• Mazdutide improved prespecified cardiometabolic measures; GI adverse events were most common and mostly mild–moderate; discontinuation rates were low (1.5%, 0.5%, 1.0%).

Clinical Implications

Mazdutide could become an additional weekly pharmacologic option for adults with overweight/obesity requiring substantial weight loss and cardiometabolic risk reduction; head-to-head and long-term outcome data will guide positioning versus existing incretin therapies.

Limitations

• Single-country (China) population limits generalizability across ethnicities.
• No head-to-head comparison with established incretin agents; long-term safety and outcomes beyond 48 weeks unknown.

Future Directions

Head-to-head trials versus semaglutide/tirzepatide, longer-term cardiovascular and renal outcomes, NASH/NAFLD endpoints, and real-world effectiveness across diverse populations.